DOI:
10.1055/s-00000036
Laryngo-Rhino-Otologie
LinksClose Window
References
Brahmer JR, Drake CG, Wollner I. et al.
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
J Clin Oncol 2010;
28: 3167-3175
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.